Kalaris Therapeutics Inc KLRS

$KLRS quite the selloff

$KLRS Pig Vomit

$KLRS still nibbling here... plenty time... good opp

$ADVB $AGLT $FIG $KLRS ADVB thank ya

Kalaris Therapeutics announced the appointment of Liisa Bayko as its new Chief Financial Officer. Bayko brings more than 20 years of biotechnology finance experience, most recently serving as Managing Director and Senior Biotechnology Analyst at Evercore ISI, where she covered small- and mid-cap biotech companies. Her background also includes senior roles at JMP Securities, Next Generation Equity Research, Prudential Equity Group, and Baker Brothers Advisors. The appointment comes as Kalaris continues patient enrollment in its Phase 1b/2 trial evaluating TH103 for treatment-naïve patients with neovascular age-related macular degeneration. TH103 is an investigational dual-target biologic designed for intravitreal administration with potential applications across multiple retinal diseases, including wet AMD, diabetic eye disease, and retinal vein occlusion. Management highlighted Bayko's expertise in biotech valuation. $KLRS

$ADVB $CCXI $FIG $KLRS ADVB halter

$ADVB $AGLT $FIG $KLRS KLRS did hold 4 but has that 200ma res

$ADVB $AGLT $FIG $KLRS